




THETA BRAINWAVE ANALYSIS WITH EEG

PARTICIPANT INFORMATION			
Identification: 0001 Gender: M Age: 23	Weight: 73 kg Height: 196 cm	BMI: 19.00	Start Date: 2025-03-03

EEG ANALYSIS						
	Date	Mean score (uV)	Mean norm (uV)	Rate score (%)	Rate norm (%)	Rate analysis
No Treatment	2025-03-03	20.84	20 ~ 50	53	51 ~ 80	
Placebo Control (Blank)	2025-03-04	15.04	20 ~ 50	45	51 ~ 80	
Mega Gold Treatment	2025-03-05	46.43	20 ~ 50	78	51 ~ 80	
TRMX 5 50th Anniversary Treatment	2025-03-06	33.40	20 ~ 50	72	51 ~ 80	
Other Brand Treatment (No Sporolife)	2025-03-07	5.70	20 ~ 50	8	51 ~ 80	



PHYSICIAN SUMMARY - KEY FINDINGS

The clinical evaluation of "Mega Gold Treatment" demonstrates its effectiveness in promoting optimal sleep transition. It achieved an A rating, with 78% theta wave activity within the 51–80% range, and an average amplitude of 46.43 μV which falls within the normal range (20–50 μV).

Conversely, "Other Brand Treatment (No Sporolife)" was associated with sleep disturbances, receiving an F rating due to only 8% theta wave activity, falling below the expected 51–80% range. Its average amplitude was 5.70 μV , significantly below the normal range (20–50 μV).

These findings highlight the superior performance of Mega Gold Treatment across all five clinical evaluations.